Related Experiment Video
Updated: Jan 11, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Endovascular Treatment for Acute Ischemic Stroke Due to Medium Vessel Occlusion: A Systematic Review with
Farsana Mustafa1, Baikuntha Panigrahi2, Partha Haldar3
1Department of Neurology, All India Institute of Medical Scienceshttps://ror.org/02dwcqs71, New Delhi, India.
Background/Objective:
The benefit of endovascular treatment (EVT) in acute ischemic strokes (AIS) due to medium vessel occlusion (MeVO) remains unclear, as recent randomized controlled trials (RCTs) have shown neutral results. This meta-analysis examines the pooled efficacy and safety of EVT in MeVO.
Methods:
A systematic review and meta-analysis of two RCTs (DISTAL and ESCAPE-MeVO) involving 1073 participants was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. The primary outcome was the risk ratios (RR) of excellent functional outcome, defined as modified Rankin score (mRS) 0-1 at 90 days. Secondary outcomes included mRS 0-2 and symptomatic intracranial hemorrhage (sICH).
Results:
The RR implied no significant difference between the two treatment arms; for the primary efficacy outcome, RR (mRS 0-1) was 0.95 (95% CI: 0.81-1.10; I2 = 0%), and for the secondary efficacy outcome, RR (mRS 0-2) was 0.98 (95% CI: 0.88-0.09; I2 = 10%). The EVT + best medical treatment (BMT) arm demonstrated a higher risk of sICH (RR: 2.39, 95% CI: 1.26-4.53; I2 = 0%) and serious adverse events (SAE) (RR: 1.32, 95% CI: 1.11-1.56; I2 = 0%), while mortality at 90 days (RR: 1.29, 95% CI: 0.94-1.76; I2 = 16%) showed no significant difference.
Conclusions:
Our study showed that, in patients with AIS due to MeVO, EVT did not lead to better outcomes at 90 days when compared to BMT and was associated with a higher risk of sICH and SAEs compared to usual care, and this result was confirmed in a trial sequential analysis.
Prospero Registration:
The study protocol was registered with the International Prospective Register of Systematic Reviews under the registration identification number CRD420250653970.
Insights
Endovascular treatment (EVT) for acute ischemic stroke (AIS) from medium vessel occlusion (MeVO) does not improve patient outcomes. EVT is linked to increased risks of symptomatic intracranial hemorrhage and serious adverse events compared to best medical treatment.
Area of Science:
- Neurology
- Interventional Cardiology
- Public Health
Background:
- Medium vessel occlusion (MeVO) accounts for a significant proportion of acute ischemic strokes (AIS).
- The efficacy and safety of endovascular treatment (EVT) for AIS due to MeVO remain uncertain, with recent randomized controlled trials (RCTs) yielding neutral results.
- This meta-analysis synthesizes evidence to clarify the role of EVT in MeVO.
Purpose of the Study:
- To evaluate the pooled efficacy of EVT in improving functional outcomes for patients with AIS due to MeVO.
- To assess the safety profile of EVT, specifically the risk of symptomatic intracranial hemorrhage (sICH) and serious adverse events (SAEs).
- To provide evidence-based insights for clinical decision-making in managing AIS with MeVO.
Main Methods:
- A systematic review and meta-analysis of two relevant RCTs (DISTAL and ESCAPE-MeVO) were performed.
- A total of 1073 participants were included in the analysis.
- Primary outcome: excellent functional outcome (modified Rankin score [mRS] 0-1 at 90 days). Secondary outcomes: mRS 0-2, sICH, and mortality.
Main Results:
- No significant difference in excellent functional outcome (mRS 0-1) between EVT and best medical treatment (BMT) was observed (RR: 0.95, 95% CI: 0.81-1.10).
- Similarly, no significant difference was found for functional outcome of mRS 0-2 (RR: 0.98, 95% CI: 0.88-0.09).
- EVT was associated with a significantly higher risk of sICH (RR: 2.39, 95% CI: 1.26-4.53) and SAEs (RR: 1.32, 95% CI: 1.11-1.56) compared to BMT.
Conclusions:
- Endovascular treatment for AIS due to MeVO does not confer better functional outcomes at 90 days compared to best medical treatment.
- EVT in this patient population is associated with an increased risk of symptomatic intracranial hemorrhage and serious adverse events.
- Trial sequential analysis confirmed these findings, suggesting that EVT is not beneficial and potentially harmful for MeVO strokes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care

